An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL).
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Nov 2016
At a glance
- Drugs Afuresertib (Primary) ; Ofatumumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 31 Oct 2016 Planned End Date changed from 1 Apr 2019 to 1 Apr 2018.
- 31 Oct 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 31 Oct 2016 Status changed from recruiting to active, no longer recruiting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History